Rib-X Pharmaceuticals' Antibiotic Development Programs to be Featured in 16 Posters and Symposium Sessions at ICAAC

- Posters and presentations including delafloxacin, radezolid and the RX-04 Program will showcase the potency and diverse utility of Rib-X's pipeline of broad-spectrum antibiotics -

NEW HAVEN, Conn.--(BUSINESS WIRE)--Sep 5, 2012 - Rib-X Pharmaceuticals, Inc. announced today that each of the Company's antibiotic development programs will be featured in posters and presentations at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 9-12, 2012 in San Francisco, CA. A total of 16 posters and symposium sessions will highlight recent developments in Rib-X's broad pipeline of antibiotic candidates. Delafloxacin will be featured in seven posters and one symposium talk, radezolid in two posters and a symposium talk, and the RX-04 program will be featured in five posters.

Delafloxacin Posters and Presentation

Delafloxacin recently successfully completed a Phase 2b trial for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in which it met or exceeded primary and secondary efficacy endpoints. It is intended for use as an effective and convenient first-line therapy primarily in hospitals prior to the availability of a specific diagnosis. Delafloxacin has the potential to offer broad-spectrum coverage as a monotherapy for serious Gram-negative and Gram-positive bacterial infections, including for methicillin-resistant Staphylococcus aureus, or MRSA, with both intravenous and oral formulations.

Data from the delafloxacin Phase 2b trial and other studies will be featured in the following posters and symposium talks:

Sunday, September 09, 2012

Poster Session 016: “In Vitro Activity of Fluoroquinolones” 11:30am-1:30pm Pacific Time

E-208 “Characterization and In Vitro Activity of Delafloxacin (DLX) Against Isolates from a Phase 2 Study of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)”

Monday, September 10, 2012

Symposium Session 078: “50 Years of Fluoroquinolones: Past, Present and Future,” 11:15am-12:45pm Pacific Time

David C. Hooper, M.D., Professor, Harvard Medical School, “New Quinolones: What's on the Horizon”

Tuesday, September 11, 2012

Poster Session 189: “Novel Agents and Insights in Skin and Soft Tissue Infections,” 11:15am-1:15pm Pacific Time

L1-1663 “Results of a Phase 2 Study of Delafloxacin (DLX) Compared to Vancomycin (VAN) and Linezolid (LNZ) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)”

L1-1667b late breaking abstract “Effect of a Single Prior Dose Short Acting Antibiotic on Clinical Efficacy in a Phase 2B Exploratory Study of Delafloxacin (DLX) Compared to Vancomycin (VAN) and Linezolid (LNZ) in Adults with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)”

L1-1667c late breaking abstract “Objective Measures of Clinical Efficacy in a Phase 2B Exploratory Study of Delafloxacin (DLX) Compared to Vancomycin (VAN) and Linezolid (LNZ) in Adults with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)”

Wednesday, September 12, 2012

Poster Session 241: “Toxicokinetics and PK/PD of New and Old Fluoroquinolones,” 9:15am-11:15am Pacific Time

A-1956 “Metabolism and Mass Balance of Delafloxacin in Healthy Human Volunteers Following Intravenous Administration”

A-1957 “Pharmacokinetics (PK) of Delafloxacin (DLX), Vancomycin (VAN) and Linezolid (LNZ) in a Phase 2 Exploratory Study in Subjects with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)”

A-1958 “A Thorough Phase 1 QTc Study of Delafloxacin (DLX) Compared with Placebo and Moxifloxacin (MXF)”

Radezolid Posters and Presentation

Radezolid is a next-generation, IV/oral oxazolidinone designed to be a potent antibiotic with a safety profile permitting long-term treatment of resistant infections, including those caused by MRSA. Radezolid has completed two Phase 2 clinical trials with an oral formulation in uncomplicated skin and skin structure infections (uSSSI) and in community acquired bacterial pneumonia (CABP). A Phase 1 study with an intravenous formulation was recently completed in healthy subjects.

Radezolid will also be featured in the following posters and symposium talks:

Tuesday, September 11, 2012

Symposium Session 154: “What Every Clinician Should Know About Emerging New Antimicrobials,” 8:30am-10:30am Pacific Time

George M. Eliopoulos, M.D., Professor of Medicine, Beth Israel Deaconess Medical Center, “New Oxazolidinones, Including Tedizolid (Torezolid, TR-700)” will summarize recent developments in the area of oxazolidinones, including radezolid

Poster Session 163: “Pharmacokinetics/Pharmacodynamics of New and Old Oxazolidinones,” 11:15am-1:15pm Pacific Time

A-1290 “A Phase 1 Single and Multiple Ascending Intravenous (IV) Dose Study of Safety and Pharmacokinetics (PK) of Radezolid (RDZ) in Healthy Subjects”

A-1289 “Radezolid Demonstrates Favorable Safety Compared to Linezolid in a Three-Month Rat Toxicology Study”

RX-04 Posters

The RX-04 program is focused on using a discrete, novel binding site within the ribosome to design and develop completely new classes of antibiotics to treat some of the most deadly and difficult-to-treat, multi-drug resistant Gram-positive and Gram-negative infections. Since its unveiling at last year's ICAAC, the program has progressed to late lead optimization. Under a collaboration and licensing agreement signed in June 2011, Sanofi has the right to develop multiple product candidates targeting this discrete binding site within the ribosome.

RX-04 will be featured in the following posters:

Tuesday, September 11, 2012

Poster Session 177: “Novel Antimicrobial Approaches and Agents” 11:15am-1:15pm Pacific Time

F-1521 “Anti-Staphylococcal and Anti-Enterococcal Activity of Novel Protein Synthesis Inhibitors from the RX-04 Program”

F-1522 “Antibacterial Activity of Novel RX-04 Compounds Against Biodefense Pathogens”

F-1523 “Novel Ribosome Inhibitors are Efficacious in a Murine Respiratory Tract Infection Model Caused by Streptococcus pneumoniae

Wednesday, September 12, 2012

Poster Session 249: “Targeting Gram-negative Pathogens” 9:15am-11:15am Pacific Time

F-2059 “Activity of Novel Pyrrolocytosine Agents Against Multidrug- and Carbapenem-Resistant Klebsiella pneumoniae

F-2072a late breaking abstract “Pharmacodynamic Assessment of RX-P873 Against Klebsiella pneumoniae Using the Murine Thigh Infection Model”

About Rib-X:

Rib-X Pharmaceuticals, Inc. is a biopharmaceutical company developing new antibiotics to provide superior coverage, safety and convenience for the treatment of serious and life-threatening infections. The Company's proprietary drug discovery platform provides an atomic-level, three-dimensional understanding of interactions between drug candidates and their bacterial targets and enables design of antibiotics with enhanced characteristics. Rib-X has two antibiotic candidates in clinical development. Delafloxacin is an enhanced spectrum IV/oral antibiotic intended for use as first-line monotherapy primarily in hospitals and recently completed a Phase 2b clinical trial for the treatment of acute bacterial skin and skin structure infections. Radezolid is a next-generation IV/oral oxazolidinone designed to be a potent antibiotic with a safety profile permitting long-term treatment of resistant infections. The Company's pipeline also includes its preclinical RX-04 program, partnered with Sanofi, S.A., and other discovery stage anti-infective programs.

Contact: Company
Rib-X Pharmaceuticals, Inc.
Bob Conerly, 203-624-5606
bconerly@rib-x.com
or
Media Relations
For Rib-X Pharmaceuticals, Inc.
Kari Watson, 781-235-3060
kwatson@macbiocom.com

 

Posted: September 2012

View comments

Hide
(web2)